Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data AbCellera Biologics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
11.6
233
375
485
38
28.8
75.1
Research and development
10.1
29.4
62.1
108
176
167
187
Selling and marketing
1.26
3.84
6.91
11.3
14.2
12.8
General and administrative
2.75
11.9
41.8
55.5
75.2
85.5
83.2
Operating expenses
15.7
77.1
171
269
275
344
292
Operating income
-4.12
156
204
217
-237
-315
-217
Interest income
0.16
0.29
3.33
16.1
42.2
38.5
28.3
Other non-operating income
1.91
1.8
14.7
22.6
63.2
114
39.5
Pre-tax income
-2.21
158
219
239
-174
-200
-178
Income tax
38.9
65.7
80.6
-27.6
-37.5
-31.2
Net income
-2.21
119
153
159
-146
-163
-146
EBITDA
-2.51
161
219
244
-213
-302
-199
EPS, basic
-0.01
0.53
0.56
0.56
-0.51
-0.55
-0.49
EPS, diluted
-0.01
0.45
0.48
0.50
-0.51
-0.55
-0.49
Shares, basic (weighted)
151
159
276
285
289
294
299
Shares, diluted (weighted)
151
263
318
315
289
294
299
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
594
476
387
133
156
129
Receivables
0.9
0
32
39.4
Inventory
0
6.34
Other current assets
5.97
21.2
75.4
55.8
67.1
111
Total current assets
813
930
1,025
872
751
728
Property, plant and equipment
17.9
112
217
Lease right-of-use assets
80.8
73.1
66.6
136
Goodwill
31.5
47.8
47.8
47.8
47.8
47.8
Intangible assets
0
115
148
132
120
42.1
38.4
Other non-current assets
8.39
30.6
46.3
94.2
96.5
51.9
Total assets
1,006
1,319
1,541
1,488
1,361
1,357
Accounts payable
7.32
14.9
14.8
28.6
34.4
25.2
Accrued liabilities
1.99
0
0
7.71
8.38
10.8
Deferred revenue
6.59
7.54
21.6
19
13.5
13.5
Short-term debt
0.19
Total current liabilities
103
121
118
119
76.6
64.3
Lease liabilities
3.72
36.4
76.7
71.2
60.7
137
Other non-current liabilities
6.62
1.73
3.09
5.91
7.17
10.4
Total liabilities
175
293
308
336
304
390
Total debt
0.19
Paid-in capital
5.92
35.4
74.1
121
166
198
Retained earnings
114
268
426
280
117
-29.5
Other comprehensive income
0.28
-1.39
-1.72
-4.38
-4.23
Shareholders' equity
10.3
831
1,026
1,233
1,152
1,056
967
Total equity
10.3
831
1,026
1,233
1,152
1,056
967
Total liabilities and equity
1,006
1,319
1,541
1,488
1,361
1,357
Shares outstanding
269
283
287
291
296
301
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-2.21
119
153
159
-146
-163
-146
Depreciation and amortization
1.6
4.84
14.5
27.8
24.4
12.5
18.4
Stock-based compensation
0.89
8.4
30.6
49.5
64.2
67.6
55.8
Deferred income tax
2.1
-2.02
-2.11
1.96
Change in receivables
-1.8
-5.47
-37.4
-22.7
-45.9
-75.1
-55.6
Change in payables
-2.09
-15.1
10.6
3.46
Cash from operations
2.69
22.7
245
277
-43.9
-109
-131
Capital expenditures
-4
-9.67
-58.5
-70.7
-76.9
-78.4
-42.8
Acquisitions
-87.6
-11.5
0
0
Purchases of investments
-275
-764
-1,022
-765
-436
Sales and maturities of investments
27.6
511
911
938
506
Cash from investing
-5.78
-120
-332
-353
-221
121
87.8
Debt issued
0.19
15.5
0.87
Debt repaid
-0.4
-19.9
-1.82
Stock issued
0.03
523
4.62
Cash from financing
0.2
684
-3.89
-1.63
10.4
12.8
14.1
Exchange rate effect
-1.43
-9.6
0.59
-2.62
1.1
Net change in cash
-2.89
587
-93
-86.5
-254
23
-28.4
Free cash flow
-1.3
13
186
207
-121
-187
-174
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $12.70 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-340.2%
Operating income / revenue.
EBITDA margin
-303.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-297.4%
Pre-tax income / revenue.
Net margin
-248.8%
Net income / revenue.
FCF margin
-180.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-143.5%
Cash from operations / revenue.
Return on equity (ROE)
-18.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-12.6%
Net income / average total assets.
Return on invested capital (ROIC)
-22.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
298.9%
Research and development expense / revenue.
Stock-based pay / revenue
77.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
37.4%
Capital expenditures / revenue.
D&A / revenue
36.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
160.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-46.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-20.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-8.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-7.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
3.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-0.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-4.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
6.2%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-1.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
2.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
12.8x
Current assets / current liabilities.
Quick ratio
2.98x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.26x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.22
Revenue / diluted weighted shares.
FCF per share
-$0.39
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.31
Cash from operations / diluted weighted shares.
Book value per share
$2.92
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
56.6x
Market cap / revenue.
P/B
4.18x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.61x
Market cap / tangible book value, when positive.
EV/Sales
54.7x
Enterprise value / revenue.
FCF yield
-3.2%
Free cash flow / market cap.
Earnings yield
-4.4%
Net income / market cap (the inverse of P/E).
What was AbCellera Biologics Inc.'s revenue in fiscal 2025?
AbCellera Biologics Inc. reported revenue of $75.1M for fiscal 2025, 160.6% higher than the year before.
Was AbCellera Biologics Inc. profitable in fiscal 2025?
No. It reported a net loss of $146.4M.
How much free cash flow did AbCellera Biologics Inc. generate in fiscal 2025?
Cash from operations of $131.3M minus capital expenditures of $42.8M left free cash flow of -$174.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.